Company intelligence / Profile preview

NeraCare

Frankfurt, Hesse, Germany

Ownership: Private
Development stage: Other

Overview

NeraCare’s Immunoprint assay identifies high-risk early-stage melanoma patients, showing clinically significant performance for relapse prediction across several prospective and archival validation studies and enabling more precise patient selection for adjuvant therapy and clinical trials. MelaGenix is the first gene-expression assay to guide adjuvant treatment selection in melanoma based on individualized risk for relapse[1][2][3][6].

Therapeutic areas: Oncology
Modalities: Molecular diagnostic testGene expression-based assayImmunohistochemistry-based test
Industry: Molecular Diagnostics

Partnerships

SkylineDx (strategic and licensing partnership)[1][4][6]Akoya Biosciences (exclusive global development/commercialization of Immunoprint)[2][6]

Beyond the preview

Go deeper on NeraCare.

Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from trial design and recruitment through results.

Trial phase
Status
Readouts

Licensing & deals

Explore licensing agreements, acquisitions, and the assets behind each deal.

Partners
Deal terms
Milestones

Funding history

Trace financing activity and the investors behind a company’s development.

Funding rounds
Investors
Capital raised

Competitive landscape

Compare peer pipelines by target, modality, and therapeutic area.

Peer companies
Targets
Pipeline overlap

Technologies & patents

Explore technology platforms and the patent landscape around relevant assets.

Platforms
Patents
Assignees

Research & analysis

Connect company news and source material to the questions you’re investigating.

Company news
Sources
Analysis

Bring the full picture into focus.

See how Gosset can support your research on NeraCare.

Explore the full profile